PFE — PFIZER INC catalysts
Next verified catalyst
2026-08-23 — A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104 · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08-23 in 17d
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination Wit
Phase 1/2 · Breast Cancer, Solid Tumors |
PFE PFIZER INC | PF-07220060 + PF-07104091 combination do |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-30 in 24d
ESTIMATED |
READOUT
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in P
Phase 3 · Multiple Myeloma |
PFE PFIZER INC | Elranatamab, Elotuzumab, Pomalidomide, D |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-08-31 in 25d
ESTIMATED |
READOUT
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults
Phase 3 · Respiratory Syncytial Virus (RSV) |
PFE PFIZER INC | RSVpreF |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given
Phase 1/2 · Breast Cancer |
PFE PFIZER INC | ARV-471, Abemaciclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-02 in 27d
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult Pe
Phase 1/2 · Pulmonary Arterial Hypertension |
PFE PFIZER INC | PF-07868489 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-15 in 1mo
ESTIMATED |
READOUT
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Over
Phase 1/2 · Obesity and Obesity-related Medical Conditions |
PFE PFIZER INC | MET233 and MET097, MET097 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-23 in 2mo
ESTIMATED |
READOUT
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad
Phase 2 · Liposarcoma, Prostate Cancer |
PFE PFIZER INC | PF-07220060, Letrozole, Fulvestrant, Mid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-19 in 2mo
ESTIMATED |
READOUT
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop
Phase 2 · Atopic Dermatitis |
PFE PFIZER INC | PF-07275315, PF-07264660 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-11-29 in 4mo
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f
Phase 3 · Menstrual Migraine |
PFE PFIZER INC | Rimegepant, Rimegepant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-02 in 4mo
ESTIMATED |
READOUT
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Ca
Phase 3 · Metastatic Castration-Resistant Prostate Cancer |
PFE PFIZER INC | PF-06821497, Enzalutamide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-02 in 4mo
ESTIMATED |
READOUT
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t
Phase 3 · Severe Alopecia Areata |
PFE PFIZER INC | Ritlecitinib higher dose, Ritlecitinib l |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-04 in 4mo
ESTIMATED |
READOUT
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D
Phase 3 · Lyme Disease |
PFE PFIZER INC | VLA15 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-21 in 5mo
ESTIMATED |
READOUT
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alop
Phase 3 · Alopecia Areata |
PFE PFIZER INC | Ritlecitinib 100 mg, Ritlecitinib 50 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|